Items Tagged ‘ELOQUENT-2 clinical trial’

July 13th, 2017

Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift

By

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti (elotuzumab) plus Revlimid (lenalidomide) continued to demonstrate effectiveness in patients with relapsed/refractory multiple myeloma compared to patients treated with Revlimid alone were recently presented in an oral session today during the 22nd Congress of the European Hematology Association in Madrid, Spain.  Combination […]

View full entry

Tags: cancer precision medicine, ELOQUENT-2 clinical trial, elotuzumab, Empliciti, lenalidomide, Multiple Myeloma, News, revlimid